Results 161 to 170 of about 38,268 (270)

Burosumab in Unidentifiable Tumor‐Induced Osteomalacia

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Tumor‐induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti‐FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for this indication in Australia.
Yi Shan Der   +5 more
wiley   +1 more source

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. [PDF]

open access: yesTheranostics, 2021
Feijtel D   +8 more
europepmc   +1 more source

Treatment of G1 Duodenal Neuroendocrine Tumors With Hepatic Metastasis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT HAIC‐FOLFOX combined with lenvatinib induced complete liver metastasis response and partial primary tumor response in G1 duodenal neuroendocrine tumor, enabling curative resection (13 months recurrence free survival), highlighting a novel conversion strategy for advanced dNETs with liver metastases.
Yuhui Fang   +7 more
wiley   +1 more source

Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2

open access: green, 2011
Andreas Stengel   +6 more
openalex   +2 more sources

Amelioration of Hypoglycemia Via Somatostatin Receptor Type 2 Antagonism in Recurrently Hypoglycemic Diabetic Rats [PDF]

open access: bronze, 2013
Jessica T.Y. Yue   +5 more
openalex   +1 more source

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 1, January 2026.
Integrated framework for tirzepatide in HFpEF management. Through metabolic, haemodynamic, structural and anti‐inflammatory pathways, tirzepatide modifies the disease trajectory of HFpEF, leading to improvements in symptoms, functional capacity and reduction in HF events.
Hamza A. Abdul‐Hafez   +9 more
wiley   +1 more source

Recent Developments in Capillary and Microchip Electroseparations of Peptides (2023–mid 2025)

open access: yesELECTROPHORESIS, Volume 47, Issue 1, Page 106-136, January 2026.
ABSTRACT This review presents a comprehensive overview of the developments and applications of high‐performance capillary and microchip electromigration methods (zone electrophoresis in a free solution or in sieving media, isotachophoresis, isoelectric focusing, affinity electrophoresis, electrokinetic chromatography, and electrochromatography) for ...
Václav Kašička
wiley   +1 more source

Home - About - Disclaimer - Privacy